Table: Daito -2025/26 parent results
10/07/2026 08:30
Jul 10 (Reuters)-
Daito Pharamaceutical Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
May 31, 2026 May 31, 2025 May 31, 2027 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 50.62 50.44
(+0.4 pct) (+8.3 pct)
Operating 3.62 2.36
(+53.3 pct) (-37.7 pct)
Recurring 3.76 2.50
(+50.6 pct) (-35.5 pct)
Net 7.81 1.51
(+416.4 pct) (-53.4 pct)
EPS 265.65 yen 49.74 yen
Ann Div 40.00 yen 70.00 yen 45.00 yen
-Q2 Div 20.00 yen 35.00 yen 22.50 yen
-Q4 Div 20.00 yen 35.00 yen 22.50 yen
NOTE - Daito Pharamaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4577.T
Recent news on Daito Pharmaceutical
See all newsTo Buy Back Up To 4.4% Of Own Shares Worth 2 Billion Yen
Table: Daito Pharmaceutical -Q1 group results
Execution Of JV And Share Transfer Agreement For Transfer Of Kyorin Pharmaceutical's Generic Drug Business To JV By Daito, Meiji Seika Pharma And Dbj
Table: Daito -2025/26 parent results
Table: Daito -2025/26 group results